Takeda Pharmaceutical Co Ltd
TAK- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001395064
In the last 90 days, Takeda Pharmaceutical Co Ltd insiders filed 0 open-market purchases and 19 sales; 379 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; no superinvestor holds it.
Other share classesTKPHF
Q3 2025 vs. Q2 2025
How the institutions holding Takeda Pharmaceutical Co Ltd changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 318 | 3 | 332 | +17 |
| Shares | 77.8M | 152.2K | 85.2M | +7.52M (+9.7%) |
| Value | $1.20B | $2.35M | $1.25B | +$46.6M (+3.9%) |
3 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (58)
Institutions that held Takeda Pharmaceutical Co Ltd at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (41)
Institutions that held Takeda Pharmaceutical Co Ltd at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (3)
Institutions that held Takeda Pharmaceutical Co Ltd at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Avantax Advisory Services, Inc. | 137,959 | $2.13M |
| Congress Wealth Management LLC | 13,378 | $206.8K |
| First Horizon Advisors, Inc. | 821 | $12.7K |